文献速递肝病

熊去氧胆酸应答与原发性胆汁性胆管炎合并代偿期肝硬化患者死亡率降低相关

Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该回顾性队列研究纳入501例原发性胆汁性胆管炎合并代偿期肝硬化患者(以男性退伍军人为主),比较UDCA应答者与部分应答者的结局。结果显示UDCA应答与肝失代偿、全因死亡或移植、肝病相关死亡或移植风险降低相关,但未显著降低肝细胞癌风险;门脉高压患者获益最大。

要点

  • UDCA应答与肝失代偿风险降低相关(sHR 0.54,95%CI 0.31-0.95,P=0.03)。
  • UDCA应答与全因死亡或移植风险降低相关(aHR 0.49,95%CI 0.33-0.72,P=0.0002)。
  • UDCA应答未显著降低肝细胞癌风险(sHR 0.39,95%CI 0.60-2.55,P=0.32)。

核心结论

  • 在 predominantly 男性PBC合并代偿期肝硬化队列中,UDCA应答与肝失代偿、全因死亡或移植、肝病相关死亡或移植风险降低相关。
  • 门脉高压患者中UDCA应答相关的获益最大。

研究设计与样本

  • 回顾性队列研究,纳入501例PBC合并代偿期肝硬化退伍军人(以男性为主)。
  • UDCA应答者287例(随访1692.8患者年),部分应答者214例(随访838.9患者年)。
  • 采用竞争风险时间更新Cox比例风险模型评估UDCA应答与结局的关联。

主要发现

  • UDCA应答者 vs 部分应答者的肝失代偿未调整发生率:3.8 vs 7.9/100患者年,P<0.0001。
  • UDCA应答者 vs 部分应答者的肝病相关死亡或移植未调整发生率:3.7 vs 6.2/100患者年,P<0.0001。
  • UDCA应答与肝失代偿风险降低相关(sHR 0.54,95%CI 0.31-0.95,P=0.03)。
  • UDCA应答与全因死亡或移植风险降低相关(aHR 0.49,95%CI 0.33-0.72,P=0.0002)。
  • UDCA应答与肝病相关死亡或移植风险降低相关(sHR 0.40,95%CI 0.24-0.67,P=0.0004),但与HCC风险无显著关联(sHR 0.39,95%CI 0.60-2.55,P=0.32)。

临床怎么用

  • 对于PBC合并代偿期肝硬化患者,应评估UDCA应答情况,应答者可能预示更好的肝脏相关预后。
  • 门脉高压患者可能从UDCA应答中获得最大获益,需重点关注。
  • UDCA应答不能替代HCC监测,仍需按规范进行肝癌筛查。

局限性

  • 回顾性队列研究,以男性退伍军人为主,结果外推需谨慎。
  • UDCA应答与部分应答的定义及评估时间点未在摘要中详述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with cirrhosis and men have been under-represented in most studies examining the clinical benefit of response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC). The aim of this study was to study the association of UDCA response and liver-related death or transplantation, hepatic decompensation, and hepatocellular carcinoma (HCC) in patients with PBC cirrhosis. METHODS: We conducted a retrospective cohort study of veterans, predominantly men, with PBC and compensated cirrhosis to assess the association of UDCA response with the development of all-cause and liver-related mortality or transplantation, hepatic decompensation, and HCC using competing risk time-updating Cox proportional hazards models. RESULTS: We identified 501 subjects with PBC and compensated cirrhosis, including 287 UDCA responders (1,692.8 patient-years [PY] of follow-up) and 214 partial responders (838.9 PY of follow-up). The unadjusted rates of hepatic decompensation (3.8 vs 7.9 per 100 PY, P < 0.0001) and liver-related death or transplantation (3.7 vs 6.2 per 100 PY, P < 0.0001) were lower in UDCA responders compared with partial responders. UDCA response was associated with a lower risk of hepatic decompensation (subhazard ratio [sHR] 0.54, 95% confidence interval [CI] 0.31-0.95, P = 0.03), death from any cause or transplantation (adjusted hazard ratio 0.49, 95% CI 0.33-0.72, P = 0.0002), and liver-related death or transplantation (sHR 0.40, 95% CI 0.24-0.67, P = 0.0004), but not HCC (sHR 0.39, 95% CI 0.60-2.55, P = 0.32). In a sensitivity analysis, the presence of portal hypertension was associated with the highest UDCA-associated effect. DISCUSSION: UDCA response is associated with a reduction in decompensation, all-cause, and liver-related death or transplantation in a cohort of predominantly male patients with cirrhosis, with the highest benefit in patients with portal hypertension.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. John BV, Khakoo NS, Schwartz KB, et al. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. Am J Gastroenterol. 2021. PMID: 33989225. doi:10.14309/ajg.0000000000001280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。